Curriculum vitae

Curriculum Vitae

Name: &= nbsp; &nbs= p; &= nbsp; Todd D. Merchen M.D.

&nb= sp;

MCG Rank= : &= nbsp; &nbs= p; 07/01/2007 - Assistant Professor of Surgery- General Surgery Section, Transplant Servi= ce and Oncology Service

MCG Title: = &= nbsp; &nbs= p; Transplant and Hepatobiliary Surgeon

Office Address: &nbs= p; &= nbsp; BA 4407

Office Telephone: &nb= sp; = 706-721-4831

Personal:

Date of Birth: &nbs= p; &= nbsp; 02/17/70

Place of Birth: &nbs= p; &= nbsp; Savannah, GA

Citizenship: &= nbsp; &nbs= p; USA

Sex: &= nbsp; &nbs= p; &= nbsp; Male

Race: &= nbsp; &nbs= p; &= nbsp; Caucasian

Marital Status: = &= nbsp; Married (Lee Ann Merchen 11/11/00)

Children: &= nbsp; &nbs= p; &= nbsp; Patrick (08/12/01) and Georgia (03/04/05= )

Education:

08/1984-07/1988 &= nbsp; Savannah Country Day School, Savannah, GA

08/1988-05/1993: &= nbsp; University of Georgi= a, Athens, GA. Bachelor of Science,

&= nbsp; &nbs= p; &= nbsp; &nbs= p; Majors in Biochemist= ry and Microbiology.

07/1993-06/1997: &= nbsp; Mercer University School of Medicine, Macon, GA.

Doctorate of Medicine

07/1997-06/2002: &= nbsp; Wright State University School of Medicine, Dayton= , OH.

General Surgery Residency

07/2002-06/2004: = University of Cincin= nati College of Medicine, Cincinnat= i,OH<= /span>

Multi-organ Transplant Surgery Fellowship

&nb= sp;

07/2005: &= nbsp; &nbs= p; = Completed Board Certification in General Sur= gery

&nb= sp;

Licensure: &= nbsp;

2007-2009 &= nbsp; &nbs= p; Georgia: (#058986)

2004-2009 &= nbsp; &nbs= p; Washington: (#MD00044042)

Clinical/Academic Positions and Appointments:

2002-200= 4 &= nbsp; &nbs= p; Transplant Fellow, University of Cincinnati College of Medicine, Departmen= t of Surgery, Division of Transplantation, Cincinnati, OH.

07/2004-= 12/2006: &= nbsp; Program Director, Kidney Transpla= nt Program and General, Transplant an= d Hepatobiliary Surgeon, Sacred Heart Medical Center, Spokane WA.

&nb= sp;

05/2006-= present: &= nbsp; &nbs= p; Clinical Instructor of Surgery, Department of Surgery, University of Washington, Seattle, WA.

&nb= sp;

Hospital Committees:

&nb= sp;

2005-200= 6: &= nbsp; &nbs= p; Created the Quality Assurance Conference within Transplant Selection Commit= tee of the Kidney Transplant Program, Sacred Heart Medical Center, Spokane, WA

&nb= sp;

2005-200= 6:        &= nbsp;           &nbs= p;         Kidney Transplant representative to the S= urgical Committee at Sacred Heart Medical Center.<= /span>

&nb= sp;

2003-200= 4:        &= nbsp;           &nbs= p;         Transplant Surgery Improvement Commit= tee at University Hospital, Cincinnati, OH.

&nb= sp;

&nb= sp;

&nb= sp;

&nb= sp;

&nb= sp;

Awards/Honors:

<= /p>
1998-199= 9:        &= nbsp;           &nbs= p;         Appointed to the House Staff Council of = Miami Valley Hospital=

1996:        &= nbsp;           &nbs= p;            &= nbsp;     Received the AMA/Glaxo= Achievement Award- annually recognizes 25 medical students nationally e= ach year for exhibiting outstanding leadership qualities.

&nb= sp;

1996:        &= nbsp;           &nbs= p;            &= nbsp;     Elected Vice-Speaker of the American Medic= al Association- Medical Student Section (AMA-MSS)- Presiding over all national meetings and ensuring fair and equitable debate= in the 700 member House of Delegates.

&nb= sp;

1996:        &= nbsp;           &nbs= p;            &= nbsp;     Appointed Alternate Delegate from Georgia to= the AMA House of Delegates-Physicians Section Annual Meeting by the Medical Association of Georgia- a position not previously given to a medical studen= t.

1996:        &= nbsp;           &nbs= p;            &= nbsp;     Elected Chairman of AMA/MSS Mercer Cha= pter

&nb= sp;

Professional Societies:

&nb= sp;

American Society of Transplantation

Americ= an College of Surgeons

American Medical Association

Washin= gton State Medical Society

Spokan= e County Medical Society

Research Projects:

"An Open-label, concentration controlled, randomized, 12 month study of Prograf, Rapamune, corticosteroids compared to cyclosporine an= d Rapamune and corticosteroids in high risk renal allog= raft recipients.”

Funded by Wyeth Ayerst Pharmaceuticals. Research Associate

&nb= sp;

"Pharmacokinetics of Immunosuppressants in Transplant patients wh= o have undergone Gastric Bypass Surgery." American College= of Clinical Pharmacy Research Institute Grant. Research Associate

"A Randomized, Open-Lab= el, Comparative Evaluation of Conversion from Calcineurin<= /span> Inhibitor Treatment to Sirolimus Treatment vers= us Continued Calcineurin Inhibitor Treatment in Li= ver Allograft Recipients Undergoing Maintenance Therapy."

Funded by = Wyeth Ayerst Pharmaceutic= als. Research Associate

"A Phase II, Open-Label, Multicenter Study to Asse= ss the Pharmacokinetics, Safelty and Tolerability in S= table Kidney Transplant Patients Converted from a Prograf Based Immunosuppression Regimen to a Modified R= elease (MR) Tacrolimus Based Immu= nosuppression Regimen."

Funding by= Fujisawa. Research Associate

&nb= sp;

"A Phase II, Open-Label, Multicenter Study to Asse= ss the Pharmacokinetics, Safelty and Tolerability in S= table Liver Transplant Patients Converted from a Prograf Based Immunosuppression Regimen to a Modified R= elease (MR) Tacrolimus Based Immu= nosuppression Regimen."

Funding by Fujisawa. Research Associate

"A Phase II, Open-Label, Multicenter Study to Asse= ss the Pharmacokinetics, Safelty and Tolerability in S= table Heart Transplant Patients Converted from a Prograf Based Immunosuppression Regimen to a Modified R= elease (MR) Tacrolimus Based Immu= nosuppression Regimen."

Funding by= Fujisawa. Research Associate

"An open-label, comparative trial of two daclizumab dosing strategies versus no induction treatment in combination with tacrolimus, mycophenolate= mofetil, and steroids for the prevention of acute all= ograft rejection in simultaneous kidney/pancreas transplant recipients."

Funded by Roche Laboratories. Research Associate

"A prospective, randomi= zed, multicenter trial of early corticosteroid cessa= tion vs. long term maintenance corticosteroid therapy in primary renal allograft= recipients treatment with tacroli= mus and mycophenolate mofetil<= /span>."

Funded by = Fujisawa Pharmaceu= ticals. Research Associate

"A Prospective, pilot s= tudy of early corticosteroid cessation with Zenapax,= Prograf, Cellcept, and Rapamune in High Immunologic Risk Renal Transplant Recipients"

Funded by Roche Laboratories. Research Associate

"A Prospective Pilot Study of Corticosteroid Avoidance with<= /p>

Prograf, = Cellcept and Rapamune that Avoids Induction Therapy in R= enal

Transplant Patients"

Funded by = Wyeth Ayerst Pharmaceutic= al Company. Research Associate

"An open-label study to evaluate the safety and efficacy of early (5 day) stero= id cessation in de novo renal allograft recipients treated with Simulect induction and Prograf in combination with Rapamune."

Funded by = Wyeth Ayerst Pharmaceutic= al. Research Associate

"A multicenter, randomized, partially-blinded study of the safety and efficacy of FTY720 combined with corticosteroids and full or reduced dose Neoral in de novo adult renal transplant recipients."

Funded Novartis Pharmaceutical Company. Research Associate

"Corticosteroid-free, <= span class=3DSpellE>Calcineurin-sparing Immunosuppre= ssion Protocol for HLA-Identical Living Donor Renal Transplant Recipients".<= span style=3D'mso-spacerun:yes'>

Funded Roc= he Laboratories. Research Associate

"A randomized, open-label, comparative evaluation of conversion from calcineurin inhibitors to siroli= mus versus continued use of calcineurin inhibitors = in renal allograft recipients."

Funded by = Wyeth Ayerst Pharmaceutic= al Company. Research Associate

&nb= sp;

"Open-Label, Randomized, Prospective Multicenter Study to Co= mpare the Efficacy and Safety among Three Immunosuppressant Treatment Regimens in Patients Receiving a Liver Transplant for End-Stage Liver Disease Caused by Chronic Hepatitis C Infection."

Funded by Roche Laboratories. Resear= ch Associate

"Rapamune Outcomes Assessment Registry."

Funded by Wyeth Ayerst Pharmaceutical Company. Resear= ch Associate

"Pharmacokinetic and Pharmacodynamic evaluation of open-label, comparative trial of two dac= lizumab dosing strategies versus no induction treatment in combination with tacrolimus, mycophenolate= mofetil, and steroids for the prevention of acute all= ograft rejection in simultaneous kidney/pancreas transplant recipients."

Funded by Roche Laboratories. Resear= ch Associate

"A Single Center, Pilot Study= of Corticosteroid Discontinuation in Liver Transplant Recipients Utilizing a <= span class=3DSpellE>Tacrolimus/Mycophenolate Mofetil= based Maintenance Immunosuppression Protocol.&q= uot;

Funded by Fujisawa Pharmaceuticals. Research Associate

"An open label randomiz= ed multicenter study to evaluate the efficacy and safety= of early calcineurin inhibitor withdrawal in recip= ients of primary renal allografts maintained long-ter= m on mycophenolate mofetiland = sirolimus.

Funding in negotiation by Roche Laboratories. Resea= rch Associate

"An open label randomiz= ed single center study to evaluate the efficacy and safety of early calcineurin inhibitor withdrawal in recipients of pri= mary renal allografts maintained long-term on mycophenolate mofetil and= sirolimus without prednisone.

Funding by Roche Laboratories. Research Associate

"A Phase III, randomized, open-label, comparative, = multicenter study to Assess the safety and efficacy o= f Prograf/MMF, Modified Release Pr= ograf/MMF and Neoral/MMF in denovo kidney transplant recipients'.

Funding by Fujisawa Healthcare Incorporated. Research Associate

"FK 7= 78 Denovo renal transplant study".

Funding by Healthcare Incorporated. Research Ass= ociate

"Rand= omized, prospective, Phase II Study comparing Thymoglobulin in a rapid discontinuat= ion of corticosteroids protocols with standard corticosteroid therapy in living donor renal transplantation using mycophenolate= mofetil and tacrolimus maintenance therapy."

Funding by= SangStat Medical Corporation. Research Associate

"Evaluation of Immune Globulin Intravenous, (Human),10%, Manufactured = By Chromatography Process (IGIV-C,10%), As An Agent To Reduce Anti-HLA Antibod= ies And Improve Transplantation Results In Cross Match Positive Living Donor Ki= dney Allograft Recipients"

Funding by NIH. Research Associate

"Extension: A Prospective Pilot Study of Corticosteroid Avoidance with Prograf, Cellcept and Rapamune that Avoids Induction Therapy in Renal Trans= plant Patients"

Funded by Wyeth Ayerst Pharmaceutical Company. Research Associate

"Clinical, Immunologic, and Pharmacologic Consequences of

Kidney and Liver Transplantation in People with HIV Infection."= <= /p>

Funding by NIH. Research Associate=

Received American Cancer Society Research Grant to fund the plastination of cancerous lung tissue with Harmon Bickley, DDS = PhD, Department of Pathology, Mercer University School of Medicine, Macon, GA.

Laboratory Research Assistant, Clanton C. Black, PhD., Department of Biochemistry, University of Georgia, Athens, GA.

Publications/ Abstracts/Presentations:<= span style=3D'font-size:14.0pt;font-family:Times;mso-bidi-font-family:Arial; font-weight:normal'>

Mer= chen T, Champion H. The AMA-MSS: Leading the Charge for Change, JAMA, <= /span>Nov. 6, 1996-Vol 276, No. 17.

Mer= chen T, Gupta M, First MR, Trofe = J, Gross TG, Beebe TM, Alloway RR, Muthiah C, Hanaway MJ, Buell JF, Woodle ES. PTLD following lung transplantation. (24) American Journal of Transplantation= 2003 3(Suppl.5):346. (oral)

Mer= chen TD, Gupta M, Hanaway MJ= , Trofe J, Beebe TM, Gross TG, All= oway RR, Buell JF, Woodle ES. Pre-e= xisting testicular cancer in solid organ transplant recipients. (756) Ame= rican Journal of Transplantation 2003 3(Suppl.5):346.(poster)

Mer= chen TD, Gupta M, Hanaway MJ= , Trofe J, Beebe TM, Gross TG, All= oway RR, Buell JF, Woodle ES. De no= vo testicular cancer in solid organ transplant recipients. (758) American Journal of Transplanta= tion 2003 3(Suppl.5):346.(poster)

Mer= chen TD, Gupta M, Hanaway MJ= , Trofe J, Beebe TM, Gross TG, All= oway RR, Buell JF, Woodle ES. Pre-e= xisting bladder cancer in solid organ transplant recipients. (757) Americ= an Journal of Transplantation 2003 3(Suppl.5):346. (po= ster)

Mer= chen TD, Gupta M, Hanaway MJ= , Trofe J, Beebe TM, Gross TG, All= oway RR, Buell JF, Woodle ES. De no= vo node positive squamous cell cancer in solid organ transplant recipients. (762) American Journal of Transplantation 2003 3(Suppl.5):347.(poster)

Merchen T, Gupta M, Gersin K, Hanaway MJ, Woodle ES, Buell JF. Laparoscopic surgery in the cirrho= tic population – is it truly safe? (poster) presented at the American Hepato-Pancreato-Biliary Association 4^th American Congress 2003.

Gupta M, Merchen TD, Trofe J, Gross TG, Beebe TM, All= oway RR, Hanaway MJ, Woodle ES, Buell JF. Pre-existing thyroid cancer is associated with a low risk of recurre= nce following solid organ transplantation. (750) American Journal of Transplanta= tion 2003 3(Suppl.5):344. (poster)

Gupta M, Merchen TD, First MR= , Trofe J, Gross TG, Beebe TM, All= oway RR, Hanaway MJ, Woodle ES, Buell JF. De novo malignancies following lung transplantation. (= 748) American Journal of Transplantation 2003 3(Suppl.5):344. (po= ster)

Gupta M, Merchen TD, First MR= , Trofe J, Gross TG, Beebe TM, All= oway RR, Woodle ES, Buell JF. Lung transplan= tation in patients with pre-existing malignancies. (749) American Journal of Transplantation 2003 3(Suppl.5):344. (poster= )

Gupta M, Merchen TD, Trofe J, Gross TG, Beebe TM, All= oway RR, Hanaway MJ, Woodle ES, Buell JF. Pre-existing prostate cancer in solid organ transplant recipients: Determining the risk of recurrence. (536)&= nbsp; American Journal of Tranplantation 2003 3(Suppl.5):288. (oral)

Gupta M, Merchen TD, Trofe J, Gross TG, Beebe TM, All= oway RR, Hanaway MJ, Woodle ES, Buell JF. De novo prostate cancer in solid organ recipients: A determination of outcomes. (136) American Journal of = Transplantation 2003 3(Suppl.5):186. (oral)

Gupta M, Merchen TD, Gross TG= , Trofe J, Beebe TM, Alloway RR, Hanaway MJ, Rudich Sm, Woodle ES, Buell JF. Liver transplantation for epithelioid hemangioendothelioma. (ora= l) presented at the International Liv= er Transplantation Society 2003.

DeSalvo D, Roy-Chaudhury P, Merchen T, Konijetti K, Gupta M, Boa= rdman R, Rogers C, hanaway M, Bu= ell J, Konoplev K, Smith R, Wo= odle ES, Peddi R.&n= bsp; West Nile virus encephalitis in o= rgan transplant recipients: Another high risk group for Men= ingoencephalitis and death? (580) American Journal of Transplantation 2003 3(Suppl.5):300. (or= al)

Chudzinski AP, Boardman RE, Gupta M, H= anaway MJ, Merchen TD, Clipp= ard M, Woodle ES, Buell= JF. Long-term analysis of graft function in right laparoscopic donor nephrectomy: a case controlled series. (1318) American Journal of Transplantation = 2003 3(Suppl.5):490. (poster)

Gearhart M, Martin J, Trumbull L, Zavala E, Wetzel D, G= upta M, Merchen T, Morel= li J, Weber F, Aranda-Michel J, Bass M, Hanaway MJ, Woodle ES, Buell JF. Financial and clinical impact of Vancomycin-resistant Enterococcus (VRE) in liver transplant recipien= ts: A double matched control study. (1436) American Journal of Transplantation 2003 3(Suppl.5):520. (poster)

Boardman RE, Alloway RR, Ro= gers C, Clippard M, Gupta M, Mer= chen T, Metze T, Suskind B, Trofe J, Peddi V= , Woodle ES. African American renal transplant recipients: Experience with early = corticoidsteroid cessation under modern immunosuppression. (812) American Journal of Surgery 2003 3(Suppl.5):175. (oral)

Rogers C, Alexander JW, Metze T, Boardman RE, Trofe J, Gupta M, Mer= chen T, Hanaway MJ, Buell JF, Cardi M, Roy-Chaudhury= P, Peddi VR, Goodman H, Se= thuraman G, Woodle ES.&= nbsp; Corticosteroid avoidance ameliorates lymphocele= formation and wound healing complications associated with Sirolimus therapy. American Journal = of Transplantation (1298) American Journal = of Transplatation = 2003 3(Suppl.5):484. (poster)

Doty TC, Merchen T, Gupta M,= Hanaway M, Amhad S, Lowy = A, Mathews J, Pennington L, Hanto D, Woodle ES, Buell JF. Comparison of= laparoscopic and open surgical management of hepatic cysts. (= poster) presented at the American Hepato-Pancreato-Biliary Association 4^th American Congress 2003.

Buell JF, Gersin K, Gupta M, Doty TC, Merchen T, Hanaway MJ, Rudich S, Woodle ES.&= nbsp; Lessons learned in a initial experience w= ith laparoscopic hepatic surgery: Operative results. (poster) presented at = the American Hepato-Pancreato-Biliary Association 4= ^th American Congress 2003.

Books/Chapters:

Eppinger M, Bolding S, Merchen T. Coronary Artery Bypass Grafting. In McKellar D, Reiling R, Eisman B (eds). Prognosis and = Outcomes in Surgical Diseases. 82-83, Qu= ality

Medical Pub, c1999: 82-83.